They also emphasize that additional randomized clinical trials involving broader populations and longer follow-up periods will be important for confirming these findings and evaluating their generalizability
In recent enforcement actions, the agency identified multiple concerns with compounded GLP-1 products: use of incorrect salt forms of semaglutide that have not been studied for safety, dosing errors due to patient-drawn injections from multi-dose vials, improper storage and shipping conditions, and misleading marketing that implies FDA equivalence
PlexusDx recommends baseline fasting glucose, HbA1c, and lipid panels, then repeat testing at 46 weeks and 12 weeks of dual therapy
Kalra, S., Kalra, B., & Sharma, A